From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
INF biosimilar (Inflectra) | INF bio-originator (Infliximab) | P-Value | |||
---|---|---|---|---|---|
N = 319 | N = 13,119 | ||||
Naïve | Prevalent | Naïve | Prevalent | ||
Number of patients | 96 | 223 | 2,149 | 10,970 | |
Age, N (%)a | < 0.0001* | ||||
< 35 | 24 (25.0) | 38 (17.0) | 581 (27.0) | 2,629 (24.0) | |
35–44 | 14 (14.6) | 30 (13.5) | 429 (20.0) | 1,935 (17.6) | |
45–54 | 21 (21.9) | 43 (19.3) | 473 (22.0) | 2,571 (23.4) | |
55–64 | 27 (28.1) | 57 (25.6) | 503 (23.4) | 2,706 (24.7) | |
≥ 65 | 10 (10.4) | 55 (24.7) | 163 (7.6) | 1,129 (10.3) | |
Female, N (%) | 63 (65.6) | 135 (60.5) | 1,330 (61.9) | 6,254 (57.0) | 0.0001* |
Region, N (%) a | < 0.0001* | ||||
Mid-West | 8 (8.3) | 55 (24.7) | 402 (18.7) | 2,225 (20.3) | |
North-East | 5 (5.2) | 10 (4.5) | 351 (16.3) | 1,808 (16.5) | |
South | 32 (33.3) | 65 (29.2) | 849 (39.5) | 4,403 (40.1) | |
West | 29 (30.2) | 71 (31.8) | 257 (12.0) | 1,318 (12.0) | |
Unknown | 22 (22.9) | 22 (9.9) | 290 (13.5) | 1,216 (11.1) | |
All-cause hospitalization, N (%) | 27 (28.1) | 39 (17.5) | 615 (28.6) | 1,466 (13.4) | < 0.0001* |
Infections, N (%) | 58 (60.4) | 121 (54.3) | 1,375 (63.9) | 6,284 (57.3) | < 0.0001* |
Any hospitalized infection during follow-up, N (%) | 0 (0.0) | 6 (2.7) | 108 (5.0) | 528 (4.8) | < 0.0001* |
Autoimmune disease, N (%) a | < 0.0001* | ||||
Rheumatoid arthritis (RA) | 51 (53.1) | 111 (49.8) | 805 (37.5) | 4292 (39.1) | |
Psoriatic arthritis (PsA) | 9 (9.4) | 23 (10.3) | 125 (5.8) | 919 (8.4) | |
Inflammatory bowel disease (IBD) | 36 (37.5) | 78 (35.0) | 1,049 (48.8) | 4,977 (45.4) | |
Others | - | 11 (4.9) | 170 (7.9) | 782 (7.1) | |
Comorbidities, N (%) | |||||
Cancer | 5 (5.2) | 6 (2.7) | 83 (3.9) | 261 (2.4) | 0.0012* |
Chronic kidney disease | 10 (10.4) | 22 (9.9) | 210 (9.8) | 938 (8.6) | 0.2721 |
Chronic obstructive pulmonary disease | 15 (15.6) | 19 (8.5) | 160 (7.5) | 727 (6.6) | 0.0087* |
Chronic heart disease | 4 (4.2) | 21 (9.4) | 105 (4.9) | 505 (4.6) | 0.0278* |
Depression | 14 (14.6) | 32 (14.4) | 341 (15.9) | 1,318 (12.0) | < 0.0001* |
Diabetes | 9 (9.4) | 37 (16.6) | 271 (12.6) | 1,275 (11.6) | 0.0838 |
Number of other baseline biologics, N (%) | < 0.0001* | ||||
None | 56 (58.3) | 198 (88.8) | 1,260 (58.6) | 9,777 (89.1) | |
One | 24 (25.0) | 21(9.4) | 647 (30.1) | 976 (8.9) | |
Two or more | 16 (16.7) | 4 (1.8) | 242 (11.3) | 217 (2.0) | |
Concurrent medications, N (%) | |||||
Antibiotics | 70 (72.9) | 144 (64.6) | 1,572 (73.2) | 7,003 (63.8) | < 0.0001* |
Betablockers | 19 (19.8) | 43 (19.3) | 309 (14.4) | 1,547 (14.1) | 0.0839 |
Hormone therapy | 17 (17.7) | 37 (16.6) | 378 (17.6) | 1,608 (14.7) | 0.0060* |
Opioids | 56 (58.3) | 115 (51.6) | 1,128 (52.5) | 4,608 (42.0) | < 0.0001* |
Nonsteroidal anti-inflammatory drugs (NSAID) | 37 (38.5) | 67 (30.0) | 660 (30.7) | 2801 (25.5) | < 0.0001* |
Statin | 16 (16.7) | 69 (30.9) | 399 (18.6) | 2206 (20.1) | 0.0003* |
Steroids | 73 (76.0) | 75 (33.6) | 1,608 (74.8) | 4,377 (39.9) | < 0.0001* |